| Budget Amount *help |
¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2015: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2014: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
|
|---|
| Outline of Final Research Achievements |
The survival rate for children with osteosarcoma has improved due to advances in treatment, including intravenous high-dose methotrexate (HD-MTX). Although HD-MTX has been associated with neurotoxic effects among survivors of childhood acute lymphoblastic leukemia (ALL) and osteosarcoma survivors received HD-MTX at cumulative dosages 4- to 5-fold greater than the children with ALL, the impact of osteosarcoma treatment on neurocognitive functioning has not been well-studied in Japan.
We evaluated the neurocognitive status of 12 children using the Wechsler Intelligence Scale for Children at baseline and annually during a 2-year follow-up period. Of the 12 children, 3 underwent the first testing one month after diagnosis and the remaining children after completion of therapy. Results from cognitive measures were converted to standardized scores using age-adjusted normative data.
|
